Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | NSCLC | Research

Development and validation of prognostic nomogram for T1-3N0M0 non-small cell lung cancer after curative resection

Authors: Weijian Mei, Wang Yao, Zhengbo Song, Wenjie Jiao, Lianxin Zhu, Qinghua Huang, Chaolun An, Jianguang Shi, Guiping Yu, Pingli Sun, Yinbin Zhang, Jianfei Shen, Chunwei Xu, Han Yang, Qian Wang, Zhihua Zhu

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Radical resection plus lymph node dissection is a common treatment for patients with T1-3N0M0 non-small cell lung cancer (NSCLC). Few models predicted the survival outcomes of these patients. This study aimed to developed a nomogram for predicting their overall survival (OS).

Materials and methods

This study involved 3002 patients with T1-3N0M0 NSCLC after curative resection between January 1999 and October 2013. 1525 Patients from Sun Yat-sen University Cancer Center were randomly allocated to training cohort and internal validation cohort in a ratio of 7:3. 1477 patients from ten institutions were recruited as external validation cohort. A nomogram was constructed based on the training cohort and validated by internal and external validation cohort to predict the OS of these patients. The accuracy and practicability were tested by Harrell's C-indexes, calibration plots and decision curve analyses (DCA).

Results

Age, sex, histological classification, pathological T stage, and HI standard were independent factors for OS and were included in our nomogram. The C-index of the nomogram for OS estimates were 0.671 (95% CI, 0.637–0.705),0.632 (95% CI, 0.581–0.683), and 0.645 (95% CI, 0.617–0.673) in the training cohorts, internal validation cohorts, and external validation cohort, respectively. The calibration plots and DCA for predictions of OS were in excellent agreement. An online version of the nomogram was built for convenient clinical practice.

Conclusions

Our nomogram can predict the OS of patients with T1-3N0M0 NSCLC after curative resection. The online version of our nomogram offer opportunities for fast personalized risk stratification and prognosis prediction in clinical practice.
Appendix
Available only for authorised users
Literature
1.
go back to reference Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.CrossRefPubMed Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.CrossRefPubMed
2.
go back to reference Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
3.
go back to reference Zhang Z, Yang S, Ma Y, et al. Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic review. Transl Lung Cancer Res. 2021;10(6):2715–32.CrossRefPubMedPubMedCentral Zhang Z, Yang S, Ma Y, et al. Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic review. Transl Lung Cancer Res. 2021;10(6):2715–32.CrossRefPubMedPubMedCentral
4.
go back to reference Ettinger DS, Wood DE, Aisner DL, et al. NCCN guidelines insights: non-small cell lung cancer, version 2. 2021. J Natl Compr Canc Netw. 2021;19(3):254–66.CrossRefPubMed Ettinger DS, Wood DE, Aisner DL, et al. NCCN guidelines insights: non-small cell lung cancer, version 2. 2021. J Natl Compr Canc Netw. 2021;19(3):254–66.CrossRefPubMed
5.
go back to reference Osarogiagbon RU, Veronesi G, Fang W, et al. Early-stage NSCLC: advances in thoracic oncology 2018. J Thor Oncol. 2019;14(6):968–78.CrossRef Osarogiagbon RU, Veronesi G, Fang W, et al. Early-stage NSCLC: advances in thoracic oncology 2018. J Thor Oncol. 2019;14(6):968–78.CrossRef
6.
go back to reference Dalwadi S, Teh BS, Bernicker E, Butler EB, Farach AM. Community-based disparities in the treatment and outcomes of early-stage non-small-cell carcinoma. Cureus. 2019;11(10):e5889.PubMedPubMedCentral Dalwadi S, Teh BS, Bernicker E, Butler EB, Farach AM. Community-based disparities in the treatment and outcomes of early-stage non-small-cell carcinoma. Cureus. 2019;11(10):e5889.PubMedPubMedCentral
7.
go back to reference Thomas PA. Intraoperative lymph-node assessment during NSCLC surgery: the need for standardisation and quality evaluation. Lancet Oncol. 2019;20(1):23–5.CrossRefPubMed Thomas PA. Intraoperative lymph-node assessment during NSCLC surgery: the need for standardisation and quality evaluation. Lancet Oncol. 2019;20(1):23–5.CrossRefPubMed
8.
go back to reference Smeltzer MP, Faris NR, Ray MA, Osarogiagbon RU. Association of pathologic nodal staging quality with survival among patients with non-small cell lung cancer after resection with curative intent. JAMA Oncol. 2018;4(1):80–7.CrossRefPubMed Smeltzer MP, Faris NR, Ray MA, Osarogiagbon RU. Association of pathologic nodal staging quality with survival among patients with non-small cell lung cancer after resection with curative intent. JAMA Oncol. 2018;4(1):80–7.CrossRefPubMed
9.
go back to reference Zhu Z, Song Z, Jiao W, et al. A large real-world cohort study of examined lymph node standards for adequate nodal staging in early non-small cell lung cancer. Transl Lung Cancer Res. 2021;10(2):815–25.CrossRefPubMedPubMedCentral Zhu Z, Song Z, Jiao W, et al. A large real-world cohort study of examined lymph node standards for adequate nodal staging in early non-small cell lung cancer. Transl Lung Cancer Res. 2021;10(2):815–25.CrossRefPubMedPubMedCentral
10.
go back to reference Zhu Z, Mei W, Song Z, et al. A standard for hilar and intrapulmonary lymph node dissection and pathological examination in early non-small cell lung cancer. Transl Lung Cancer Res. 2021;10(12):4587–99.CrossRefPubMedPubMedCentral Zhu Z, Mei W, Song Z, et al. A standard for hilar and intrapulmonary lymph node dissection and pathological examination in early non-small cell lung cancer. Transl Lung Cancer Res. 2021;10(12):4587–99.CrossRefPubMedPubMedCentral
11.
go back to reference Gesthalter Y, Smyth R, Sullivan D. Treatment of early-stage non-small cell lung cancer. Am J Respir Crit Care Med. 2022;205(4):P7–8.CrossRefPubMed Gesthalter Y, Smyth R, Sullivan D. Treatment of early-stage non-small cell lung cancer. Am J Respir Crit Care Med. 2022;205(4):P7–8.CrossRefPubMed
12.
go back to reference Donington JS, Kim YT, Tong B, et al. Progress in the management of early-stage non-small cell lung cancer in 2017. J Thor Oncol. 2018;13(6):767–78.CrossRef Donington JS, Kim YT, Tong B, et al. Progress in the management of early-stage non-small cell lung cancer in 2017. J Thor Oncol. 2018;13(6):767–78.CrossRef
13.
go back to reference Gao L, Shen L, Wang K, Lu S. Propensity score matched analysis for the role of surgery in stage small cell lung cancer based on the eighth edition of the TNM classification: a population study of the US SEER database and a Chinese hospital. Lung Cancer (Amsterdam, Netherlands). 2021;162:54–60.CrossRefPubMed Gao L, Shen L, Wang K, Lu S. Propensity score matched analysis for the role of surgery in stage small cell lung cancer based on the eighth edition of the TNM classification: a population study of the US SEER database and a Chinese hospital. Lung Cancer (Amsterdam, Netherlands). 2021;162:54–60.CrossRefPubMed
14.
go back to reference Rami-Porta R. Future perspectives on the TNM staging for lung cancer. Cancers (Basel). 2021;13(8):1940.CrossRefPubMed Rami-Porta R. Future perspectives on the TNM staging for lung cancer. Cancers (Basel). 2021;13(8):1940.CrossRefPubMed
16.
go back to reference D’Cunha J, Herndon JE 2nd, Herzan DL, et al. Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial. Lung cancer (Amsterdam, Netherlands). 2005;48(2):241–6.CrossRefPubMed D’Cunha J, Herndon JE 2nd, Herzan DL, et al. Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial. Lung cancer (Amsterdam, Netherlands). 2005;48(2):241–6.CrossRefPubMed
17.
go back to reference Zuo Z, Zhang G, Song P, et al. Survival nomogram for stage IB non-small-cell lung cancer patients, based on the SEER database and an external validation cohort. Ann Surg Oncol. 2021;28(7):3941–50.CrossRefPubMed Zuo Z, Zhang G, Song P, et al. Survival nomogram for stage IB non-small-cell lung cancer patients, based on the SEER database and an external validation cohort. Ann Surg Oncol. 2021;28(7):3941–50.CrossRefPubMed
18.
go back to reference Zeng Q, Li J, Tan F, et al. Development and validation of a nomogram prognostic model for resected limited-stage small cell lung cancer patients. Ann Surg Oncol. 2021;28(9):4893–904.CrossRefPubMedPubMedCentral Zeng Q, Li J, Tan F, et al. Development and validation of a nomogram prognostic model for resected limited-stage small cell lung cancer patients. Ann Surg Oncol. 2021;28(9):4893–904.CrossRefPubMedPubMedCentral
19.
go back to reference Cao X, Zheng YZ, Liao HY, et al. A clinical nomogram and heat map for assessing survival in patients with stage I non-small cell lung cancer after complete resection. Ther Adv Med Oncol. 2020;12:1758835920970063.CrossRefPubMedPubMedCentral Cao X, Zheng YZ, Liao HY, et al. A clinical nomogram and heat map for assessing survival in patients with stage I non-small cell lung cancer after complete resection. Ther Adv Med Oncol. 2020;12:1758835920970063.CrossRefPubMedPubMedCentral
20.
go back to reference Liang W, Zhang L, Jiang G, et al. Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer. J Clin Oncol. 2015;33(8):861–9.CrossRefPubMed Liang W, Zhang L, Jiang G, et al. Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer. J Clin Oncol. 2015;33(8):861–9.CrossRefPubMed
21.
go back to reference Qi Y, Wu S, Tao L, et al. Development of nomograms for predicting lymph node metastasis and distant metastasis in newly diagnosed T1–2 non-small cell lung cancer: a population-based analysis. Front Oncol. 2021;11: 683282.CrossRefPubMedPubMedCentral Qi Y, Wu S, Tao L, et al. Development of nomograms for predicting lymph node metastasis and distant metastasis in newly diagnosed T1–2 non-small cell lung cancer: a population-based analysis. Front Oncol. 2021;11: 683282.CrossRefPubMedPubMedCentral
22.
go back to reference Li Q, Zhang P, Wang Y, et al. T4 extension alone is more predictive of better survival than a tumour size >7 cm for resected T4N0-1M0 non-small-cell lung cancerdagger. Eur J Cardiothorac Surg. 2019;55(4):682–90.CrossRefPubMed Li Q, Zhang P, Wang Y, et al. T4 extension alone is more predictive of better survival than a tumour size >7 cm for resected T4N0-1M0 non-small-cell lung cancerdagger. Eur J Cardiothorac Surg. 2019;55(4):682–90.CrossRefPubMed
23.
go back to reference Gu C, Huang Z, Dai C, et al. Prognostic analysis of limited resection versus lobectomy in stage IA small cell lung cancer patients based on the surveillance, epidemiology, and end results registry database. Front Genet. 2018;9:568.CrossRefPubMedPubMedCentral Gu C, Huang Z, Dai C, et al. Prognostic analysis of limited resection versus lobectomy in stage IA small cell lung cancer patients based on the surveillance, epidemiology, and end results registry database. Front Genet. 2018;9:568.CrossRefPubMedPubMedCentral
24.
go back to reference Shi Y, Wu S, Ma S, et al. Comparison between wedge resection and lobectomy/segmentectomy for early-stage non-small cell lung cancer: a bayesian meta-analysis and systematic review. Ann Surg Oncol. 2022;29(3):1868–79.CrossRefPubMed Shi Y, Wu S, Ma S, et al. Comparison between wedge resection and lobectomy/segmentectomy for early-stage non-small cell lung cancer: a bayesian meta-analysis and systematic review. Ann Surg Oncol. 2022;29(3):1868–79.CrossRefPubMed
25.
go back to reference Cheng YF, Hung WH, Chen HC, et al. Comparison of treatment strategies for patients with clinical stage T1–3/N2 lung cancer. J Natl Compr Canc Netw. 2020;18(2):143–50.CrossRefPubMed Cheng YF, Hung WH, Chen HC, et al. Comparison of treatment strategies for patients with clinical stage T1–3/N2 lung cancer. J Natl Compr Canc Netw. 2020;18(2):143–50.CrossRefPubMed
26.
go back to reference Fiorelli A, Mauro I, Cicchitto G, et al. Lobar or sublobar resections are safe procedures for management of early lung cancer. Ann Trans Med. 2019;7(Suppl 3):S107.CrossRef Fiorelli A, Mauro I, Cicchitto G, et al. Lobar or sublobar resections are safe procedures for management of early lung cancer. Ann Trans Med. 2019;7(Suppl 3):S107.CrossRef
27.
go back to reference Widder J, Van De Wauwer C, Langendijk JA. Lobectomy or sublobectomy for small non-small-cell lung cancer: the question remains. J Clin Oncol. 2017;35(5):572–3.CrossRefPubMed Widder J, Van De Wauwer C, Langendijk JA. Lobectomy or sublobectomy for small non-small-cell lung cancer: the question remains. J Clin Oncol. 2017;35(5):572–3.CrossRefPubMed
Metadata
Title
Development and validation of prognostic nomogram for T1-3N0M0 non-small cell lung cancer after curative resection
Authors
Weijian Mei
Wang Yao
Zhengbo Song
Wenjie Jiao
Lianxin Zhu
Qinghua Huang
Chaolun An
Jianguang Shi
Guiping Yu
Pingli Sun
Yinbin Zhang
Jianfei Shen
Chunwei Xu
Han Yang
Qian Wang
Zhihua Zhu
Publication date
01-12-2023
Publisher
BioMed Central
Keywords
NSCLC
NSCLC
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11158-w

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine